Objective: To systematically study the anti-fibrotic effect of N-acetyl-seryl-as partyl-lysyl-proline (Ac-SDKP) on pulmonary fibrosis. Methods: In May 2021, a computer search was performed on CNKI, Wanfang Knowledge Service Platform, VIP.com, China Biomedical Literature Database, Pubmed, OVID and other databases. The retrieval time was from January 2008 to May 2021. Randomized controlled experiments on the inhibition of pulmonary fibrosis by Ac-SDKP were screened. The control group was the pulmonary fibrosis model group and the experimental group was the Ac-SDKP treatment group. The quality of the literature was assessed using the syrcle risk of bias assessment tool, and data were extracted. Data analysis was Performed using revman 5.4 software. Results: 18 papers were included, with a total of 428 animal models. The results of meta analysis showed that the contents of α-smooth muscle actin (α-SMA), type I collagen, type Ⅲ collagen, transforming growth factor-β (TGF-β) and Nodule area in the exPerimental group were lower than those in the control grouP. [SMD=-2.44, 95%CI (-3.71--1.17), P=0.000][SMD=-5.36, 95%CI (-7.13--3.59), P=0.000] [SMD=-3.07, 95%CI (-4.13--2.02), P<0.000][SMD=-2.88, 95%CI (-3.63--2.14), P=0.000] [SMD=-1.80, 95%CI (-2.42--1.18), P=0.000], the content of hydroxy proline in the experimental group was higher than that in the control group [SMD=7.62, 95%CI (4.90-10.33), P=0.000], all indexes included in the literature were statistically significant. Conclusion: Ac-SDKP has obvious inhibitory effect on the process of pulmonary fibrosis, and may become a new clinical drug for the treatment of pulmonary fibrosis.
目的： 通过Meta分析研究N-乙酰基-丝氨酰-天门冬氨酰-赖氨酰-脯氨酸（Ac-SDKP）对肺纤维化的抗纤维化作用。 方法： 于2021年5月，检索中国知网、万方数据库、维普、中国生物医学文献数据库、PubMed、OVID数据库，检索时间为2008年1月至2021年5月，筛选关于Ac-SDKP抑制肺纤维化的随机对照试验，其中对照组为肺纤维化模型组，实验组为Ac-SDKP治疗组。采用SYRCLE风险偏倚评估工具进行文献质量评价，并提取数据，采用RevMan5.4软件进行数据分析。 结果： 纳入文献18篇，总计动物模型428个。Meta分析结果显示：与对照组比较，实验组的α-平滑肌肌动蛋白（α-SMA）、Ⅰ型胶原、Ⅲ型胶原、转化生长因子-β（TGF-β）及结节面积各指标含量均降低[SMD=-2.44，95%CI（-3.71~-1.17），P=0.000]、[SMD=-5.36, 95%CI（-7.13~-3.59），P=0.000]、[SMD=-3.07, 95%CI（-4.13~-2.02）；P= 0.000]、[SMD=-2.88, 95% CI（-3.63~-2.14），P=0.000]、[SMD=-1.80, 95% CI（-2.42~-1.18），P=0.000] ，羟脯氨酸含量更高[SMD=7.62 ，95%CI（4.90~10.33），P=0.000]。 结论： Ac-SDKP对肺纤维化进程具有明显的抑制作用，并可能成为治疗肺纤维化的一种新的临床药物。.
Keywords: Animal model; Meta-analysis; N-acetyl-seryl-aspartyl-lysyl-proline; Pulmonary fibrosis; Silicosis.